Abstract:Background: Langerhans cell histiocytosis (LCH) is the most common benign tumor in children, however its etiology remains incompletely understood. This aim of this study was to employ bioinformatics methods to identify differentially expressed genes (DEGs) in LCH patients. The identification of these DEGs can offer novel insights and research directions for the prevention, early diagnosis, and treatment of LCH. Methods: Gene expression data from GSE122476 was retrieved from the Gene Expression Omnibus (GEO) database. Using the R language, differentially expressed genes (DEGs) were identified between normal blood samples and bone tissue samples from LCH patients. The DEGs were subjected to functional and pathway analysis utilizing the DAVID database. The functional analysis, pathway enrichment, and protein-protein interactions of these genes were further examined using DAVID and STRING. To identify core network genes and significant protein interaction modules, Cytoscape software was employed. Results: A total of 229 DEGs were identified, comprising 107 up-regulated genes and 122 down-regulated genes. GO and KEGG enrichment analyses showed that the up-regulated DEGs were involved in processes such as immune response, hypoxia response, cell apoptosis, lipid antigen binding, and membrane composition. On the other hand, down-regulated DEGs were associated with inflammation, positive regulation of MAP kinase activity, and serine-type endopeptidase inhibitor activity. The KEGG enrichment analysis showed that the up-regulated DEGs exhibited significant enrichment in hematopoietic cell lineage, the interaction between viral proteins and cytokines and their receptors, TNF signaling pathway, cell apoptosis, and Th1, Th2, and Th17 cell differentiation. Conversely, the down-regulated DEGs were significantly enriched in cytokine receptor interaction, lysosome, and the PI3K-AKT signaling pathway. Further analysis using the STRING database resulted in the identification of 10 key genes within the protein network interaction map. These genes included TNF, CD69, IL7R, CCL4, IL3RA, CD1C, TNFRSF9, HAVCR2, IL2RG, and GZMA. Conclusion: In this study, 10 DEGs were identified as potential candidate diagnostic biomarkers for LCH patients. While these DEGs hold promise for their potential utility in LCH diagnosis, it is important to note that further experiments are required to validate their functional pathways and elucidate their roles as hub genes associated with LCH.

The plasma‐soluble CSF1R level is a promising prognostic indicator for pediatric Langerhans cell histiocytosis

Immune Microenvironment Associated with the Severity of Langerhans Cell Histiocytosis in Children.

Serum soluble CD25 levels were associated with prognosis of children with Langerhans cell histiocytosis

Evaluation of Soluble Colony Stimulating Factor 1 Receptor (CSF1R) in Peripheral Blood As a Diagnostic Marker of CSF1R-Related Disorder (CSF1R-RD) in a Murine Model and CSF1R-RD Patients.

BRAF‐V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first‐line therapy

The clinical impact of serum soluble CD25 levels in children with Langerhans cell histiocytosis

A Risk Model Composed of Complete Blood Count, BRAF V600E and MAP2K1 Predicts Inferior Prognosis of Langerhans Cell Histiocytosis in Children

CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis

Clinical Outcomes and Prognostic Risk Factors of Langerhans Cell Histiocytosis in Children: Results from the BCH‐LCH 2014 Protocol Study

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Overexpression of Lymphoid Enhancer‐binding Factor‐1 (LEF1) is a Novel Favorable Prognostic Factor in Childhood Acute Lymphoblastic Leukemia

Correlation of Plasma MiR-146a,MiR-223 Levels with the Prognosis of Childhood with Acute Lymphoblastic Leukemia

Bioinformatics Analysis of Potential Key Genes and Pathways in Pediatric Patients with Langerhans Cell Histiocytosis

Proteomic analysis of cerebrospinal fluid in pediatric acute lymphoblastic leukemia patients: a pilot study.

Rapid Detection of Neoplastic Cells in Serous Cavity Effusions in Children with Flow Cytometry Immunophenotyping.

CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia

The Baseline Metabolism Parameters of 18F‑FDG PET/CT As Promising Prognostic Biomarkers in Pediatric Langerhans Cell Histiocytosis.

Biomarkers in Pediatric Hemophagocytic Lymphohistiocytosis With Central Nervous System Involvement: A Cohort Study

Transcriptomic landscape of circulating mononuclear phagocytes in Langerhans cell histiocytosis at the single-cell level

Clinical significance of cerebrospinal fluid soluble CD25 in pediatric hemophagocytic lymphohistiocytosis with central nervous system involvement

Abstract P-184